Replies to post #212021 on Biotech Values

[Rocky3]

So a prior report (1/20/17) shows the Pamrevlumab estimates in neoadjuvant pancreatic cancer. They start in 2022 at $60MM, going to $429MM in 2025; but are then reduced to "probability weighted sales" stating at $12MM, going to $85MM.